The first wave of pandemic influenza (H1N1) 2009 in Germany: From initiation to acceleration by Poggensee, Gabriele et al.
Poggensee et al. BMC Infectious Diseases 2010, 10:155
http://www.biomedcentral.com/1471-2334/10/155
Open Access RESEARCH ARTICLE
© 2010 Poggensee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Research article The first wave of pandemic influenza (H1N1) 2009 
in Germany: From initiation to acceleration
Gabriele Poggensee, Andreas Gilsdorf, Silke Buda, Tim Eckmanns, Hermann Claus, Doris Altmann for RKI Working 
Group Pandemic Influenza, Gérard Krause and Walter Haas*
Abstract
Background: The first imported case of pandemic influenza (H1N1) 2009 in Germany was confirmed in April 2009. 
However, the first wave with measurable burden of disease started only in October 2009. The basic epidemiological 
and clinical characteristics of the pandemic were analysed in order to understand the course of the pandemic in 
Germany.
Methods: The analysis was based on data from the case-based, mandatory German surveillance system for infectious 
diseases. Cases notified between 27 April and 11 November 2009 and fulfilling the case definition were included in the 
study.
Results: Two time periods with distinct epidemiologic characteristics could be determined: 23,789 cases (44.1%) 
occurred during the initiation period (IP, week 18 to 41), and 30,179 (55.9%) during the acceleration period (AP, week 42 
to 45). During IP, coinciding with school summer holidays, 61.1% of cases were travel-related and one death occurred. 
Strict containment efforts were performed until week 32. During AP the majority of cases (94.3%) was autochthonous, 
12 deaths were reported. The main affected age group shifted from 15 to 19 years in IP to 10 to 14 years in AP (median 
age 19 versus 15 years; p < 0.001). The proportion of cases with underlying medical conditions increased from 4.7% to 
6.9% (p < 0.001). Irrespective of the period, these cases were more likely to be hospitalised (OR = 3.6 [95% CI: 3.1; 4.3]) 
and to develop pneumonia (OR = 8.1 [95% CI: 6.1; 10.7]). Furthermore, young children (0 to 2 years) (OR = 2.8 [95% CI: 
1.5; 5.2]) and persons with influenza-like illness (ILI, OR = 1.4 [95% CI: 1.0; 2.1]) had a higher risk to develop pneumonia 
compared to other age groups and individuals without ILI.
Conclusion: The epidemiological differences we could show between summer and autumn 2009 might have been 
influenced by the school summer holidays and containment efforts. The spread of disease did not result in change of 
risk groups or severity. Our results show that analyses of case-based information can advise future public health 
measures.
Background
Only a few days after the World Health Organization
announced on 24 April 2009 a Public Health Emergency
of International Concern caused by a new influenza virus
variant, the first imported case of pandemic influenza
(H1N1) 2009 was confirmed in Germany [1]. Interna-
tional travel facilitated the geographical spread from the
initial foci of infection in Mexico and the United States to
many countries throughout the world, seeding urban cen-
tres with a high intensity of transmission before wider
geographical spread within countries occurred [2]. In
summer 2009, most countries reported increasing case
numbers, however, differences in patterns and intensity
of transmission ranging from sustained human-to-
human transmission in some areas to local transmission
in others were observed. While on average 50% of the
cases in Europe were travel-related during the summer
months, noticeable geographical differences were seen. In
July 2009, in the UK a sharp increase in the proportion of
locally acquired infections was observed [3]. At the same
time, in Germany the proportion of cases associated with
travel to European countries continued to rise, with the
majority of infections in travellers returning from Spain -
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a major holiday destination [4]. In contrast to other Euro-
pean countries no influenza-associated deaths were
reported until 25 September 2009. The first wave of the
H1N1 pandemic with measurable disease burden at the
population level in Germany started only in October
2009.
Based on the surveillance data we analysed the basic
epidemiological and clinical characteristics of pandemic
influenza (H1N1) 2009 infection in order to understand
the course of the pandemic in Germany. Furthermore we
investigated factors associated with hospitalisation and
the occurrence of pneumonia to provide new as well as
verify existing evidence on risk groups for severe disease
and resulting recommendations.
Methods
T he analyses were based upon da ta fr om two sour ces:
The national surveillance system for notifiable infectious
diseases and the sentinel surveillance system for acute
respiratory diseases (ARI).
In 2001, the German national electronic surveillance
system (SurvNet@rki) was established. Case-based infor-
mation is transmitted electronically by the local health
authorities via the state health authorities to the Robert
Koch Institute, which is the national public health insti-
tute (RKI) [5]. Transmitted data sets include information
on age, sex, date of symptom onset, hospitalisation, and
country of infection, amongst others.
Cases notified between 27 April 2009 (week 18) and 11
November 2009 (week 45) which fulfilled the following
case definition were included in the analyses:
• Any case with detection of nucleic acid of pandemic 
influenza (H1N1) 2009 by real-time PCR [6], regard-
less of clinical presentation (laboratory-confirmed 
case),
• any case with fever and acute respiratory symptoms 
or death from unexplained acute respiratory illness 
with contact to a laboratory-confirmed case (epide-
miological linked case).
Influenza-like illness is defined as acute onset of respi-
ratory symptoms, and fever, and cough, and headache or
musculo-skeletal pain. Risk factors for severe courses are
defined as chronic diseases (cardio-vascular disease,
respiratory disease, immunosuppression, diabetes, other
chronic diseases), obesity (body mass index > 30), and
pregnancy. This additional information was gathered for
each case using a defined free-text format available in
SurvNet@rki starting in week 18 and expanded to
retrieve more detailed information in weeks 26 and 43
(see annex).
The burden of disease is measured by syndromic senti-
nel surveillance. The sentinel surveillance system of acute
respiratory illness (ARI; defined as acute pharyngitis,
bronchitis or pneumonia with or without fever) was
established in Germany in 1992, since summer 2006 a
year-round sentinel surveillance of influenza was imple-
mented. Since week 16/2009 the sentinel surveillance is
exclusively performed by the sentinel physicians and the
RKI. Data from approx. 400 (summer) to 650 (winter)
actively reporting sentinel sites are transmitted weekly to
the Robert Koch Institute. An index ("Practice index"; PI)
for each participating sentinel site (surgery/practice) is
calculated weekly by the "Arbeitsgemeinschaft Influenza"
(http://influenza.rki.de). The PI is defined as the relative
deviation of observed consultations for ARI divided by all
consultations in the same week and set into relation to
the background value of this ratio in weeks without influ-
enza virus circulation. Background ARI activity during
winter is set at the threshold PI of 115.
Age was calculated based on the notified year and
month of birth. The age group of school-aged children
was defined as 5 to 14 years. Categorical variables are
presented as percentages with interquartile ranges and
continuous variables are presented with interquartile
range where appropriate. Bivariate analysis was done to
compare two groups using the chi-square test for cate-
gorical and the Mann-Whitney test for continuous vari-
ables. Odds were calculated including 95% confidence
intervals. Unconditional logistic regression models were
performed including all variables of interest to investigate
the association of hospitalisation and pneumonia with
independent variables. Analyses were performed using
PASW Statistics 17.0 (SPSS Inc, Chicago, USA).
As one of the possible factors with impact on the course
of the pandemic the timing of the school holidays was
analysed. In Germany the school vacation times differ
between the 16 Federal States. We calculated the vacation
density for the observation period and defined it as the
mean proportion of the population per week living in
States with on-going school holidays (http://
www.schulferien.org/inverser_Ferienkalender/
ferientermine_2009_invers.html).
Results
General epidemiological features
As of 11 November 2009 a total of 53,968 cases and 13
deaths was reported from week 18 through week 45 to
the RKI. The most frequent reported symptoms were
fever (80.7%) and cough (77.8%). Acute onset of disease
was reported in 22.4% of the cases.
Weeks 18 through 28 were characterised by low num-
bers of reported cases. From week 29 to 35 an increased
number of cases was reported with a peak of more than
3,500 cases in week 31. The peak was followed by a lower
plateau with 850 to 1,500 newly reported cases per week
(week 36 to 41). From week 42 onwards the number of
reported cases started to increase steeply forming the
first wave of autochthonous transmission of pandemicPoggensee et al. BMC Infectious Diseases 2010, 10:155
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influenza (H1N1) 2009 in Germany (figure 1). During the
summer no increased influenza activity was detected by
the syndromic sentinel surveillance, however, from week
42 onwards the nationwide ARI activity was for the first
time above the baseline activity threshold with pro-
nounced increased activity in the southern part of Ger-
many, especially in Bavaria (figure 2).
From week 18 to 32 information on contact tracing was
available for 2,896 (26%) of 11,283 notified cases (figure
3). For these cases 21,717 contact persons were reported.
In average (median), 3 contact persons per case were
identified and followed up (lower and upper quartile: 2, 6;
range: 1 person to 330 persons), no contact persons were
traced for 133 pandemic influenza cases (4.6%). For 2,388
follow-up events information was available on whether
Figure 1 Cases of pandemic influenza (H1N1) 2009 virus infection in Germany by source of origin by week as of 11 November 2009. (n = 
53,968).
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antiviral prophylaxis has been given to the contact per-
sons. Between week 18 and 23 antiviral prophylaxis was
given to 71.0% to 100% of the contact persons dropping to
10.3% in week 32.
We defined an initiation and acceleration period of the
pandemic in Germany based on the results of the syndro-
mic sentinel surveillance and routine surveillance:
Initiation period with cases diagnosed between week 18
and 41 and acceleration period with cases diagnosed in
weeks 42 to 45. From week 42 onwards the number of
notified cases started to rapidly increase for the second
time after the smaller peak in week 31. Furthermore, in
week 42 the Practice Index increased above the back-
ground winter activity of acute respiratory infection
(threshold: PI >115).
Comparison of periods
In table 1 the comparison of cases of the initiation period
versus cases of the acceleration period is shown: Out of
the 53,968 cases reported to the RKI as of 11 November
2009, 23,789 cases (44.1%) occurred during the initiation
period and 30,179 cases (55.9%) during the acceleration
period.
During the initiation period, 61.1% of cases were travel-
related, whereas during the acceleration period 94.3%
were autochthonous (table 1). The distribution over time
is shown in figure 1.
Figure 4 shows the age distribution of cases over the
weeks. In the initiation period the age group 15 to 24
years constituted 54% of all cases (n = 12,854) dropping to
24.7% (n = 7.441) in the acceleration period. The propor-
tion of school-aged children in the age group 5 to 14 years
increased from 16% (n = 3,794) in the initiation period to
43.8% (n = 13,195) in the acceleration period. The median
age decreased significantly from 19 years in the initiation
period to 15 years in the acceleration period (p < 0.001;
table 1).
O n  a v e r a g e ,  2 9 %  o f  t h e  G e r m a n  p o p u l a t i o n  l i v e d  i n
States with school holidays during the observation period
between weeks 18 and 45. Vacation density peaks in the
time period between weeks 29 and 34 reflecting the main
school holidays during summer months in Germany and
coinciding with the peak of reported cases during the ini-
tiation period. No marked difference in the mean weekly
vacation density between the two time periods was found
(initiation period: 29%; acceleration period: 30%). How-
ever, after week 37 the vacation density dropped to 0% for
two continuous weeks (39 and 40) just prior to the rise
above the threshold of the syndromic surveillance (figure
2).
The proportion of cases where the reported symptoms
were in accordance with the case definition for influenza-
like illness (ILI) did not differ between the two periods
and was as low as 9.7% (Table 1).
Figure 3 Number of trace back events by number of contacts traced per case with pandemic influenza (H1N1) 2009 infection in Germany, 
week 18 to 32 in 2009. The green line represents the number of notified pandemic influenza (H1N1) 2009 cases; the bars present the number of 
contact persons followed-up per case of pandemic influenza A/c.
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Table 1: Characteristics of cases of pandemic influenza reported in the initiation period (week 18 to week 41, 2009) and 
acceleration period (week 42 to week 46, 2009)
Number of cases 
with information
Initiation 
period (%)a
Acceleration 
period (%)a
Total 53,968 23,789 (44.1) 30,179 (55.9)
Age groups 53,930 23,783 30,147
Median [quartiles] 19 [16,26]# 15 [10,26]#
0-4 years 2,076 516 (2.2) 1,560 (5.2)
5-14 years 16,989 3,794 (16.0) 13,195 (43.8)
15-24 years 20,295 12,854 (54.0) 7,441 (24.7)
25-59 years 13,975 6,398 (26.9) 7,577 (25.1)
≥ 60 years 595 221 (0.9) 374 (1.2)
Origin of infection 53,757 23,714 30,043
Autochthonous cases 37,573 9,235 (38.9) 28,338 (94.3)
Risk factors 39,748 17,579 22,169
All cases 820 (4.7)* 1,539 (6.9)*
Autochthonous cases 27,486 411/6,868 (6.0)** 1,458/20,618 (7.1)**
Imported cases 12,140 405/10,644 (3.8)** 77/1,476 (5.2)**
Risk factors
Chronic diseases
Respiratory disease 1,080 372 (2.1) 708 (3.2)
Cardio-vascular disease 264 107 (0.6) 157 (0.7)
Diabetes 173 63 (0.4) 110 (0.5)
Obesity§ 159 71 (0.4) 88 (0.4)
Immunosuppression 112 40 (0.2) 72 (0.3)
Other chronic diseases 458 127 (0.7) 331 (1.5)
Pregnancy 113 40 (0.2) 73 (0.3)
Age groups 39,748 17,533 22,043
0-4 years 1,474 17/367 (4.6) 53/1.107 (4.8)
5-14 years 12,351 101/2,831 (3.6) 571/9,520 (6.0)
15-24 years 15,107 314/9,510 (3.3) 291/5,597 (5.2)
25-59 years 10,368 350/4,711 (7.4) 560/5,657 (9.9)
≥ 60 years 429 38/157 (24.2) 63/272 (23.2)
Symptoms 53,968 23,789 30,179
ILI 2,318 (9.7) 2,924 (9.7)
Diagnosis
Time interval between onset of symptoms and diagnosis 7.253 3 days [2, 5]# 2 days [1,4]#Poggensee et al. BMC Infectious Diseases 2010, 10:155
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In table 1, information is given on risk factors of cases
(chronic diseases, obesity, pregnancy) during the two
periods. Overall the proportion of cases with reported
risk factors was significantly higher in the acceleration
period compared to the initiation period (6.9% vs. 4.7%; p
< 0.001). The proportion of reported cases with risk fac-
tors increased in the acceleration period for all age groups
except for cases older than 60 years. In both periods the
proportion of cases with risk factors was significantly
higher in patients who acquired the infection in Germany
(initiation period: 5.7% versus 3.6%; p < 0.004; accelera-
tion period: 6.6% versus 4.8%: p < 0.0001).
The time interval between onset of symptoms and the
time of diagnosis decreased from the initiation to the
acceleration period from 3 days to 2 days and the time
between onset of symptoms and initiation of treatment
from 2 days to 1 day (table 1). The proportion of cases
with initiated antiviral treatment dropped from 29.3% in
the initiation period to 24.7% in the acceleration period,
while it increased for cases with and decreased for cases
without underlying conditions.
During the initiation period a higher proportion of
cases was hospitalised (4.7% versus 3.4%) and the median
age of hospitalised patients was 19 years compared to 15
years in the acceleration period.
The analysis of factors associated with hospitalisation
and development of pneumonia (table 2) showed that
pneumonia was highly associated with being hospitalised
(OR = 25.5 [95% CI: 20.0; 32.5]). Among risk factors for
hospitalisation, immunosuppression (OR = 10.8 [95% CI:
7.1; 16.3]) and pregnancy (OR = 8.6 [95% CI: 5.5; 13.5])
were also highly associated with hospitalisation. In the
univariate analysis highest risks of developing pneumonia
were seen in cases with immunosuppression (OR = 14.9
[95% CI: 6.9; 32.7]) and obesity (OR = 13.8 [95% CI: 6.9;
27.5]). Having any risk factor was associated with a 7.6-
higher risk of developing pneumonia [95% CI: 5.7; 9.8].
In the multivariate analyses controlling for the period
of the pandemic, patients with risk factors and children
aged 0 to 2 years were more likely to be hospitalised. Fur-
thermore, these patient groups and additionally individu-
Antiviral treatment initiated 35,160 15,941 19,219
All cases 4,671 (29.3) 4.491 (24.7)
Cases with underlying chronic disease 2,092 319/743 (42.9) 598/1,278 (46.8)
Cases without risk factors 33,139 4,352/15,198 (28.6) 3,893/17,941 (21.7)
Pregnancy 88 6/34 (17.6) 13/54 (24.1)
Time interval between symptom onset and start of therapy 2 days [1,3]# 1 day [1,2]#
Pneumonia 40,729 18,090 22,639
All cases with pneumonia 275 93 (0.5) 182 (0.8)
Antiviral treatment initiated 219 33/77 (42.9) 56/142 (39.4)
Cases with underlying chronic disease 76 19/764 (2.5) 57/1,410 (4.0)
Cases without risk factors 176 66/16,303 (0.4) 110/20,192 (0.5)
Pregnancy 99 1/37 (2.7) 1/62(1.6)
Hospitalisation 52,485 23,665 28,820
All cases hospitalised 2,084 1,117 (4.7)* 967 (3.4)*
Age (years) 19 [16,26]# 15 [11,26]#
Cases with risk factors 2,342 102/814 (12.5) 182/1,528 (11.9)
Age (years) 23 [16,41] # 17 [11, 39] #
Cases without risk factors 37,187 618/16,711 (3.7)* 597/20.476 (2.9)*
Age (years) 19 [16,25]# 15 [10,25]#
# Lower/upper quartile
§ Obesity requiring treatment or body mass index > 30
a The percentages in brackets refer to the number of cases with available information regarding the variable. In each cell the number printed in 
bold is used as denominators in a cell. If another denominator is used, it is given in the table.
* Comparison initiation versus acceleration period: p < 0.001
** Comparison initiation versus acceleration period: p < 0.01
Table 1: Characteristics of cases of pandemic influenza reported in the initiation period (week 18 to week 41, 2009) and 
acceleration period (week 42 to week 46, 2009) (Continued)Poggensee et al. BMC Infectious Diseases 2010, 10:155
http://www.biomedcentral.com/1471-2334/10/155
Page 7 of 12
als who had ILI or fever were more likely to develop
pneumonia.
Discussion
The analysis of the first 50,000 cases of pandemic influ-
enza (H1N1) 2009 in Germany showed a first increase of
cases in early summer comparable to the epidemiological
situation in other European countries in week 31 and 32
[7,8], but the first wave with autochthonous cases
occurred later than e.g. in the United Kingdom, which
saw a considerable increase of cases already as early as
week 28 [9]. In Germany , despite a relevant number of
cases per week in summer, the peak levelled off and the
first wave only started in week 42. With descriptive analy-
sis of surveillance data from mandatory notification and
syndromic surveillance of acute respiratory illness we
show that the epidemiologic characteristics differed
markedly between the summer months and the fall,
allowing definition of two distinct time periods.
One of the most obvious differences observed was the
proportion of imported cases in both periods. Over half
of the cases were imported in the initiation period, while
o n l y  5 %  i n  t h e  a c c e l e r a t i o n  p e r i o d  w e r e  t r a v e l - r e l a t e d .
During the summer, compared to other European coun-
tries a much lower in-country transmission occurred in
Germany . ECDC reported in beginning of A ugust tha t
only 29% of reported cases in Europe were travel-related
[10].
A very clear age shift between the two periods was
noticed. In the initiation period Germany had a very high
proportion of cases in the 15 to 24 years age group, in the
later period there was a strong shift to the younger 5 to 14
years age groups. A large proportion of cases in the sum-
mer peak were high school graduates and young adults,
who got infected while on summer travels. Behavioural
factors of the young adults during the holidays (such as
close contacts with peers, partying) might have had an
influence on the transmission within this age group [11].
It is known, that school children play an important role in
the transmission of influenza [12-14]. But during the
summer peak, pandemic influenza did hardly spread
within this group in Germany. This might be explained by
the timing of the summer school holidays which started
between weeks 27 and week 31 in the different Federal
States (Figure 2). Since mid October, after the autumn
holidays the school-aged children started to be more
affected.
Another factor that could have contributed to a
reduced transmission in the summer was the relatively
strict contact tracing efforts done by the local public
health authorities [15]. Contact tracing resulted mainly in
recommendations to cases and household contacts
including personal hygiene (e.g., hand washing, use of
face masks, and segregation within the household) and
prophylactic antiviral treatment. It has been described
that non-pharmaceutical interventions can reduce the
transmission of influenza within households if imple-
mented within 36 hours of the index patient's symptom
onset [16]. Individual case management efforts dwindled
in most local public health authorities at the peak of the
initiation period (week 32), as the number of cases
became too high to be able to continue contact tracing.
Figure 4 Age distribution of cases with pandemic influenza (H1N1) 2009 infection in Germany from week 24 to week 45 in 2009; age dis-
tribution in weeks 24 to 41 (initiation period) and in weeks 42 to 45 (acceleration period).
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Table 2: Factors influencing hospitalisation of individuals affected by pandemic influenza (H1N1) 2009 and risk factors for 
the development of pneumonia.
Independent variables n Individuals 
hospitalised/
with pneumonia 
(%)
Univariate 
analysis OR 
(95%CI)
p-value Multivariate 
analysis OR 
(95%CI)
p- value
Hospitalisation
Pneumonia 275 130 (47.3) 25.5 (20.0;32.5) <0.001 18.2 (13.6;23.9) <0.001
No pneumonia reported 40,236 1,366 (3.4) reference
Risk factors present 2,342 284 (12.1) 4.6 (3.6;4.7) <0.001 3.6 (3.1;4.3) <0.001
No risk factor reported 37,187 1,215 (3.3) Reference
Chronic disease 2,250 261 (11.6) 3.8 (3.3;4.4) <0.001
No chronic disease reported 37,298 1,240 (3.3) Reference
Immunosuppression 112 30 (26.8) 10.8 (7.1;16.3) <0.001
No risk factor reported 37,187 1,215 (3.3) reference
Respiratory disease 1,072 87 (8.1) 2,6 (2,1; 3,3) <0.001
No risk factor reported 37,187 1,215 (3.3) reference
Obesity* 159 19 (11.9) 4.0 (2,5; 6,5) <0.001
No risk factor reported 37,187 1,215 (3.3) reference
Cardio-vascular disease 260 34 (13.1) 4.5 (3.1; 6.4) <0.001
No risk factor reported 37,187 1,215 (3.3) reference
Diabetes 172 19 (11.0) 3.7 (2.3; 5.9) <0.001
No risk factor reported 37,187 1,215 (3.3) reference
Other chronic disease 70 70 (15.4) 5.4 (4.1; 7.0) <0.001
No risk factor reported 37,187 1,215 (3.3) reference
Pregnancy 106 25 (25.6) 9.9 (6.1;16.0) <0.001
No pregnancy reported 16,957 527 (3.1) reference
Age
0 - 2 years 920 107 (11.6) 3.3 (2.7;4.1) <0.001 2.9 (2.2;3.8) <0.001
All other age groups 51,563 1,977 (3.8) reference
3 - 14 years 17,486 509 (2.9) 0,6 (0.5;0.7) <0.001 0.7 (0.6;0.8) <0.001
All other age groups 34,997 1,575 (4.5) reference
Male 27,345 1,114 (4.1) 1.1 (0.9;1.2) = 0.069 1.1 (0.9;1.2) = 0.224
Female 24,628 927 (3.8) reference
Acceleration period 28,820 967 (3.4) 0.7 (0.6; 0.8) <0.001 0.8 (0.7;0.9) = 0.020
Initiation period 23,663 1,117 (4.7) reference
Pneumonia
Risk factors 2,162 76 (3.5) 7.4 (5.7;9.8) <0.001 8.1 (6.1;10.7) <0.001
No risk factor reported 36,305 177 (0.5) reference
Chronic disease 2,082 75 (3.6) 7.6 (5.8;9.9) <0.001Poggensee et al. BMC Infectious Diseases 2010, 10:155
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No chronic disease reported 36,402 179 (0.5) reference
Immunosuppression 103 7 (6.8) 14.9 (6.9;32.7) <0.001
No risk factor reported 36,305 177 (0.5) reference
Respiratory disease 994 34 (3.4) 7.2 (4.9;10.5) <0.001
No risk factor reported 36,305 177 (0.5) reference
Obesity* 143 9 (6.3) 13.8 (6.9;27.5) <0.001
No risk factor reported 36,305 177 (0.5) reference
Cardio-vascular disease 243 5 (2.1) 4.3 (1.7;10.4) = 0.002
No risk factor reported 36,305 177 (0.5) reference
Diabetes 157 1 (0.6) 1.3 (0.2;9.4) = 0.790
No risk factor reported 36,305 177 (0.5) reference
Other chronic disease 425 18 (4.2) 9.1 (5.5;14.8) <0.001
No risk factor reported 36,305 177 (0.5) reference
Pregnancy 95 2 (2.1) 4.6 (1.1;19.0) = 0.074
No pregnancy reported 17,194 80 (0.5) reference
Age
0 - 2 years 712 15 (2.1) 3.3 (1.9;5.5) <0.001 2,8 (1.5;5.2) <0.001
All other age groups 40,019 261 (0.7) reference
3 - 14 years 13,453 92(0.7) 1.1 (0.8;1.3) = 0.914
All Other age groups 27,278 184 (0.7) reference
Male 21,158 146 (0.7) 1.1 (0.7;1.4) = 0.413 1.1 (0.8;1.4) = 0.545
Female 19,228 120 (0.6) reference
Acceleration period 22,640 182 (0.8) 1.6 (1.2;2.0) = 0.001 1.3 (1.0;1.7) = 0.038
Initiation period 18,081 94 (0.5) reference
ILI** 4,442 39 (0.9) 1.3 (1.0;1.8) = 0.090 1.4 (1.0;2.1) = 0.032
No ILI 36,289 237 (0.7) reference
Fever (>38.5°C) 34,905 258 (0.7) 1.9 (1.2;3.1) = 0.007 2.0 (1.2;3.5) = 0.013
No fever reported 4,826 18 (0.4) reference
* Obesity requiring treatment or body mass index > 30
** ILI: acute onset of symptoms and fever and cough and headache or musculoskeletal pain
Table 2: Factors influencing hospitalisation of individuals affected by pandemic influenza (H1N1) 2009 and risk factors for 
the development of pneumonia. (Continued)
More research is needed to assess to what extent public
health measures and school holidays had an impact on
the course of the pandemic in the initiation period.
The proportion of cases with risk factors increased sig-
nificantly from initiation period to acceleration period.
As the recommendation changed in August 2009 to only
diagnose and treat persons with higher risks for develop-
ing severe disease, it was anticipated, that the reported
number of cases without underlying conditions would
drop. Furthermore, the fact that infection was associated
with travel in the beginning of the influenza pandemic
might have played a role ("healthy travellers"). It might be
assumed that people with health problems travel less, and
had therefore less chance of infection in the initiation
period. It is conceivable, that the change in the propor-
tion of cases with underlying conditions was more related
to these factors than to a change of the pathogenicity of
the virus, which so far did not occur [17].Poggensee et al. BMC Infectious Diseases 2010, 10:155
http://www.biomedcentral.com/1471-2334/10/155
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The decrease in hospitalisation rates might be
explained by physicians' better knowledge of the disease.
In the beginning many affected individuals were hospital-
ised, either out of anxiety or for infection control reasons
[1]. Early admission to hospital at the beginning of the
pandemic due to uncertainty in relation to the clinical
presentation and likely progression of disease has been
described in other European Countries [7,18]. Further-
more, physicians were aware about the recommendations
regarding the patient management. An increased time
interval between onset of symptoms and diagnosis and/
or treatment possibly due to higher numbers of cases in
the acceleration period did not occur as there was no
overloading of the health system in Germany. On the
contrary, the opposite happened and - as recommended -
treatment was initiated on average earlier during the
acceleration period.
Other known factors might have also influenced the
course of the pandemic in Germany, e.g. seasonality. In
general, temperature and humidity can serve as proxy for
seasonality and possibly have direct and indirect effects
on the spread of disease. These parameters have been
suggested to have an impact on the barrier function of the
nasal mucosa, and on the other hand can influence
behaviour (i.e., longer stay in confined spaces) thus
increasing the risk of transmission [19,20]. As a proxy for
this complex interaction of environmental factors, in
week 42 a temperature drop was observed shortly before
the start of the acceleration period in Germany. However,
this observation requires a more detailed study in which
regional geographic meteorological conditions and long-
term trends are compared to the respective epidemiologi-
cal dynamics of the pandemic in Europe.
In order to assess if the change in the dynamic of spread
was also reflected by more severe disease, especially
among defined priority groups, factors associated with
hospitalisation and the development of pneumonia as
proxies for severity were analysed. Unsurprisingly, pneu-
monia was highly associated with being hospitalised. As
in other studies, immunosuppression and pregnancy
were also highly associated with hospitalisation [7,21].
The univariate analysis of risk factors for developing
pneumonia shows that all reported underlying conditions
(except diabetes) were positively associated. It could be
shown that obesity had a strong association, which has
already been described in other studies [22,23]. However,
the high association we found could also be seen as a
proxy for underlying pulmonary or cardio-vascular dis-
eases. The risk to have pneumonia was 8 times higher in
people with risk factors compared to people without. The
analyses draw a special focus on young children up to two
years, who had nearly a three fold higher risk of being
hospitalised and developing pneumonia compared to the
other age groups. While the risk of hospitalisation was
lower in the acceleration period; the risk of pneumonia
among cases without underlying risk factors did not dif-
fer by time period.
Certain limitations of the study have to be kept in mind.
The data collection with regard to additional information
such as the underlying chronic diseases and pregnancy
was performed by an additional free-text format. The for-
mat was limited in space, therefore only one risk factor
(underlying chronic disease or obesity or pregnancy)
could be reported and an analysis of the impact of multi-
ple underlying health conditions was not possible. Bias
might have been introduced by missing data on clinical
parameters and therapy. Information on the risk factors
were only collected from June 2009 onwards (see annex).
Due to high case numbers in the acceleration period local
health authorities might not have been able to collect the
data due to limited human resources. Furthermore, clini-
cal information and information on therapy were often
not available. In the acceleration period, again due to lim-
ited resources, efforts to collect epidemiological data
might have been biased toward more severe disease and
hospitalised persons.
Conclusions
The comparison of the epidemiological and clinical data
of the pandemic influenza (H1N1) 2009 cases indicated
that important differences could be observed between the
i n i t i a t i o n  p e r i o d  d u r i n g  t h e  s u m m e r  m o n t h s  a n d  t h e
acceleration period with the beginning of the first wave.
Different factors might have played a role: School holi-
days reducing the number of social contacts between
school-aged children, the initial introduction of pan-
demic influenza in the group of adolescents and young
adults, and seasonality. But also the strict containment
strategy in the beginning of the pandemic could have
contributed to the fact, that Germany experienced its
first autochthonous wave much later than other Euro-
pean countries. More severe cases were seen in young
children, in patients with initial influenza-like illness and
individuals with underlying conditions. However, the
spread of the disease did not result in a change of severity
in Germany over time.
Our results show that the analyses of case-based data
can help to anticipate changes of the epidemic and inform
about mainly affected groups and therefore advice future
public health measures.
Appendix
Public health strategies, enhanced surveillance and legal 
basis
According to the Infectious Disease Act (Infektionss-
chutzgesetz, IfSG) laboratories have to notify to the local
health authorities the detection of influenza virus, this
obligation includes new subtypes of influenza virus. OnPoggensee et al. BMC Infectious Diseases 2010, 10:155
http://www.biomedcentral.com/1471-2334/10/155
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30 April 2009, a legal act came into force, obliging physi-
cians to report suspected cases, clinically diagnosed
cases, confirmed cases, and deaths of pandemic influenza
(H1N1) 2009.
Enhanced surveillance of pandemic influenza was
implemented based on a surveillance case definition for
pandemic influenza A/H1N1 differentiating between sus-
pected, probable, and confirmed cases. With the evolu-
tion of the pandemic and the adaptation of the strategy
from containment to protection and finally mitigation,
the case definition was adopted three times (May 2009,
August 2009, and October 2009).
Starting from 30 April 2009 (week 18) besides informa-
tion gathered routinely for each notified case according
to the IfSG, the following additional information was col-
lected using a standardised free-text format: classification
of cases (possible, probable, confirmed, discarded case),
in-country transmission, number of contacts followed-
up, antiviral prophylaxis of contacts. From 21 July 2009
onwards (week 29), the variables of the free-text were
changed in order to collect more detailed data on the
treatment of cases (start of therapy, antiviral drug used),
risk factors (chronic diseases, pregnancy, obesity (body
mass index > 30), presence of pneumonia, hospitalisation
and source of infection. Starting on 20 October 2009
(week 43), information on vaccination against pandemic
influenza was included.
After the detection of the first case, a public health
response strategy of containment was established. Diag-
nosed cases were isolated (mainly home isolation). Close
contacts of laboratory diagnosed cases of pandemic influ-
enza (H1N1) 2009 (e.g., household members, medical
care) were quarantined for 7 days and were asked to
check the temperature twice daily and to report to the
local health authority. Other contact persons were
advised to check the temperature daily for 7 days, to avoid
contact to vulnerable persons and to contact the local
health authorities immediately at onset of symptoms. On
18 August 2009 (week 33) the public health response
strategy changed, aiming now to protect vulnerable
groups until the availability of a vaccine against pandemic
influenza. Close contacts of cases working with vulnera-
ble groups were requested to avoid contact with these
groups; however, home quarantine was not requested any
more. For other contacts only general information on
pandemic influenza, health monitoring, and hygiene were
given.
With the availability of the pandemic vaccine in Octo-
ber 2009 and the recommendations of the Standing Com-
mittee on Vaccination giving priority for the vaccination
of medical staff and persons with risk factors, the protec-
tion of vulnerable groups by using contact management
ceased to be a task of the local health authorities. At the
same time vaccine prevention and early diagnosis and
treatment of severe cases became the focus of the strategy
to mitigate the consequences of the pandemic. On 2
November 2009 the notification act was changed, physi-
cians have been only obliged to report deaths of persons
if an infection with pandemic influenza (H1N1) 2009 was
diagnosed in temporal connection with the death. End of
October 2009 the vaccination against pandemic influenza
started in all federal states.
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